Nanjing Company Profile
What is the competitive landscape for NANJING
NANJING has four approved drugs.
There is one US patent protecting NANJING drugs.
Summary for Nanjing
| US Patents: | 1 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Nanjing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nanjing | CELECOXIB | celecoxib | CAPSULE;ORAL | 213598-001 | May 13, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nanjing King Friend | LIRAGLUTIDE | liraglutide | SOLUTION;SUBCUTANEOUS | 218115-001 | Apr 2, 2025 | AP1 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nanjing King Friend | NICARDIPINE HYDROCHLORIDE | nicardipine hydrochloride | INJECTABLE;INJECTION | 216819-001 | Aug 20, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nanjing Delova | QAMZOVA | meloxicam | SOLUTION;INTRAVENOUS | 217593-001 | Apr 22, 2025 | RX | Yes | Yes | 12,059,423 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nanjing Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 102843054 | ⤷ Start Trial |
| South Korea | 20210007951 | ⤷ Start Trial |
| Japan | 7374501 | ⤷ Start Trial |
| Japan | 2021521212 | ⤷ Start Trial |
| China | 110464846 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2019214715 | ⤷ Start Trial |
| China | 116327959 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Nanjing Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2488169 | C202330042 | Spain | ⤷ Start Trial | PRODUCT NAME: COCRISTAL DE TRAMADOL, OPCIONALMENTE EN FORMA DE UNA SAL FISIOLOGICAMENTE ACEPTABLE, Y CELECOXIB; NATIONAL AUTHORISATION NUMBER: 89051; DATE OF AUTHORISATION: 20230925; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 89051; DATE OF FIRST AUTHORISATION IN EEA: 20230925 |
| 2209800 | 132014902311502 | Italy | ⤷ Start Trial | PRODUCT NAME: INSULINA DEGLUDEC/LIRAGLUTIDE(XULTOPHY); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/947, 20140918 |
| 2209800 | SPC/GB14/079 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, OR SALTS THEREOF, AND LIRAGLUTIDE, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, OR SALTS THEREOF; REGISTERED: CH 65041 20140912; UK EU/1/14/947 20140922 |
| 0944648 | SPC/GB09/058 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: LIRAGLUTIDE; REGISTERED: UK EU/1/09/529/001 20090630 |
| 2209800 | 1490067-4 | Sweden | ⤷ Start Trial | PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918 |
| 2209800 | C300698 | Netherlands | ⤷ Start Trial | PRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918 |
| 2597103 | 2017/015 | Ireland | ⤷ Start Trial | PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; NAT REGISTRATION NO/DATE: EU/1/14/947 20140918; FIRST REGISTRATION NO/DATE: 65041 20140912 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
